US20240415953
2024-12-19
Human necessities
A61K39/215
The patent application describes innovative oral vaccine compositions designed to prevent and treat COVID-19 and its related complications, such as cytokine storm. These vaccines contain hydrolyzed and heat-inactivated antiviral antisense and other nucleic acid components targeting the expression of SARS-CoV-2 viral proteins. Notably, these compositions are stable at room temperature and aim to stimulate a comprehensive immune response, including humoral, cellular, and mucosal immunity.
This technology intersects several scientific disciplines, including molecular biology, virology, immunology, and vaccinology. It specifically focuses on creating oral formulations for COVID-19 prevention and treatment that can also aid in recovering from COVID-related organ damage. The goal is to address the shortcomings of current injectable vaccines and treatments available for COVID-19.
COVID-19 has resulted in significant global health and economic challenges, with millions affected worldwide. Although existing vaccines have shown high efficacy rates, issues such as vaccine hesitancy, the emergence of new variants, and limitations in immune response types persist. Current vaccines primarily target spike proteins prone to mutations and are not room temperature stable. Moreover, severe side effects have been reported. There is also a lack of approved treatments for cytokine storm complications associated with COVID-19.
The proposed oral vaccine compositions include hydrolyzed and heat-inactivated antiviral antisense components such as small interfering RNAs (siRNAs) targeting SARS-CoV-2 proteins. These compositions may also contain hydrolyzed SARS-CoV antigens and immune-modulating agents with anti-inflammatory properties. The components are embedded in a matrix containing salts of various metals like magnesium or calcium, enhancing stability and delivery.
These compositions are formulated for oral administration but can be adapted for other delivery methods if necessary. They are designed to remain stable at room temperature for extended periods without refrigeration. The aim is to administer these compositions to effectively stimulate a broad immune response against both wild-type SARS-CoV-2 and its variants, potentially offering an accessible alternative to current vaccines.